About

Vioti Pharmaceuticals, a newly established SPV, will operate as a Contract Development & Manufacturing Organisation (CDMO) and partner to the global biotech pharmaceutical industry in the areas of biologic drug research, development and manufacturing of the final product, to address the rising demand in biologics

Solution & Product

Almost all companies in the pharmaceutical market utilise a network of CDMOs to provide services from basic ingredients to final products, highlighting the success of the CDMO business model. Pharma companies globally, both mature and startups, lack capacity in manufacturing biologic drug substances and drug products. Moreover, the biologics market size has been growing significantly exhibiting an even stronger upward potential. Vioti has developed a fully-scaled sustainable framework to build a state-of-the-art production plant specialising in innovative, biologic medicines.

Innovation & Scalability

As the demand in biologic medicines is expected to demonstrate a strong growth, Vioti has developed a detailed business plan for growing the business in phases. The first phase involves the construction of the production plant and the purchase of top-notch equipment. In the following phases, the production capacity will be gradually increased within the existing facilities. The increase in production capacity has already been planned, having reserved space in the production plant to install additional production lines. The production capabilities will be further increased, through extending the building within the existing land area.

Traction & achievements

•Concept & Basic Design completed, fully aligned with EU and US regulations’ requirements •Evaluation and selection of suppliers, definition of equipment’s technical specifications and final selection •Evaluation and selection of constructors, aligned with the highest quality standards for drug manufacturing plants •Selection of land in an Industrial Area, building permit issued, ready to kick-off construction •Organisational chart and recruitment plan in place •Business plan fully developed, constantly reviewed & revised according to the latest market insights •Advanced commercial discussions with key leading pharmaceutical companies, several RFPs submitted to collaborate as soon as the plant is operational

Team & Why Us

Global team comprises of top-class experts in the pharmaceutical market in research, development, manufacturing, marketing and commercialisation of drugs offering in-depth expertise in contract service provisioning

Funding Needs

A c.€60m investment seeking outside investors and/or creditors